Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X:
“Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome.
Pooled analysis of PI/II data, Olutasidenib pooled MDS data show a high ORR (59%), CR ~27%, median DOR ~14.6 mo and median CR duration ~20.5 mo; median OS ~27.2 mo (small pooled cohort, n≈19 evaluable).
Cross-trial comparison; ivosidenib in MDS (image 2): ORR was ~83% with CR ~39%, and median duration of response NR, mOS 36 months.”
Title: Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome
Authors: Jorge E. Cortes, Jay Yang, Gail J. Roboz, Shira N. Dinner, Eunice S. Wang, Andrew H. Wei, Hua Tian, Francois di Trapani, Maria R. Baer, William Donnellan, Justin M. Watts
More posts featuring Talha Badar on OncoDaily.
